Florence Boisgerault
Evry, 91000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency.
Journal: Molecular therapy. Advances
Published: November 18, 2025
Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector.
Journal: Molecular therapy. Methods & clinical development
Published: July 09, 2020
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.
Journal: Nature communications
Published: March 10, 2018
Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.
Journal: Science translational medicine
Published: December 23, 2016
Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors.
Journal: Hepatology (Baltimore, Md.)
Published: November 08, 2016
The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer.
Journal: Current gene therapy
Published: December 29, 2014
Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: October 21, 2014
Hypoxic culture conditions enhance the generation of regulatory T cells.
Journal: Immunology
Published: January 31, 2014
Prolonged gene expression in muscle is achieved without active immune tolerance using microrRNA 142.3p-regulated rAAV gene transfer.
Journal: Human gene therapy
Published: February 23, 2013
MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 31, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026